Merrill Lynch maintains Vertex at neutral

Vertex Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating. Merrill Lynch said it would like to review the rating pending data disclosure of VX-950 for hepatitis C and more information on regulatory and development timelines for VX-950 and VX-702 for rheumatoid arthritis. The company recently announced a development focus on VX-950, VX-702 and a new drug candidate for cystic fibrosis. Shares of the Cambridge, Mass.-based biotechnology company were down $0.08, or 0.35%, at $22.55 on volume of 1,029,060 shares versus the three-month running average of 1,473,820 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.